58MO Evaluation of three pexidartinib doses in a global phase IV clinical study of patients with tenosynovial giant cell tumor (TGCT) who chose to continue treatment

58MO Evaluation of three pexidartinib doses in a global phase IV clinical study of patients with tenosynovial giant cell tumor (TGCT) who chose to continue treatment

Saved in:
Bibliographic Details
Published in:ESMO open Vol. 9; p. 102448
Main Authors: Stacchiotti, S., Wagner, A.J., Garcia, I.C. Carrasco, Cesari, M., Gordon, M., Lin, C-C., Papai, Z., Ryan, C.W., Tap, W.D., Trent, J.C., Gelderblom, H., Grimison, P., Pousa, A. Lopez, Van Tine, B.A., Rubinacci, M., Tecson, K., Wooddell, M., Desai, J.
Format: Journal Article
Language:English
Published: Elsevier Ltd 01-03-2024
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
ISSN:2059-7029
2059-7029
DOI:10.1016/j.esmoop.2024.102448